SELECTED NEUROLOGIC AND PSYCHIATRIC OUTCOMES IN PATIENTS TREATED WITH CLOZAPIN (Review Article)
DOI:
https://doi.org/10.52340/jecm.2022.02.21Abstract
Clozapine is a second-generation antipsychotic mostly used for treatment-resistant schizophrenia and acute suicidality. Although clozapine’s efficacy is well-documented, it has various side effects which need to be promptly addressed. In this article, we focus on neurological and psychiatric side effects. Among these side effects, seizure is a well-known complication of clozapine therapy. The articles that we reviewed concerning seizures and EEG changes in association with clozapine plasma levels and doses, found significant relations in some but not all cases. In addition to seizures, extrapyramidal side effects are common adverse effects of clozapine which can be an acute or chronic condition. Clozapine is also associated with ocular disturbances such as retinal pigmentation. It has also been shown to cause cataplexy. Moreover, clozapine can cause significant sedation. Effects of clozapine on sleep is still a controversial subject. The studies demonstrate inconsistent results. Cholinergic rebound syndrome is a rare complication of longterm clozapine use, which itself can be the inducer of insomnia. Apart from this, hypersalivation is one of the most frequent side effects with a paradoxical pathophysiology. Finally, clozapine is associated with severe psychiatric side effects, some of which need prompt intervention.
Downloads
References
Varma S, Bishara D, Besag FM, Taylor D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol 2011;1(2):47-66.
Kikuchi YS, Sato W, Ataka K, et al. Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia. Neuropsychiatr Dis Treat 2014; 10:1973-78.
Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54(9):327-30.
Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. J Psychopharmacol 2019;33(10):1187-98.
Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994;55(4):142-45.
Takeshima M, Ishikawa H, Kikuchi Y, Kanbayashi T, Shimizu T. Successful Management of Clozapine-induced Akathisia with Gabapentin Enacarbil: A Case Report. Clin Psychopharmacol Neurosci 2018;16(3):346–48.
Mathews M, Gratz S, Adetunji B, George V, Basil B. Antipsychotic-Induced Movement Disorders Evaluation and Treatment. Psychiatry (Edgmont) 2005;2(3):36–41.
Borovik AM, Bosch MM, Watson SL. Ocular pigmentation associated with clozapine. The Medical journal of Australia 2009;190(4):210-11.
Nebhinani N, Avasthi A, Modi M. Oculogyric Crisis with Clozapine: A Case Report and Review of Similar Case Reports in the Literature. Indian J Psychol Med. 2015 Jul-Sep; 37(3): 342–344.
Chiles JA, Cohn S, McNaughton A. Dropping Objects: Possible Mild Cataplexy Associated with closapin. J Nerv Ment Dis 1990;178(10):663-64.
Desarkar P, Goyal N, Khess CRJ. Clozapine-Induced Cataplexy. The Journal of Neuropsychiatry and Clinical Neurosciences 2007.
Iqbal MM, Swati S, Aneja A, Iqbal MT, Aneja E, Haque S. Most Common Side Effects of Clozapine and Their Management. International Journal of Emergency Mental Health and Human Resilience 2016;18(4):1-6.
Armitage R, Cole D, Suppes T, Ozcan ME. Effects of clozapine on sleep in bipolar and schizoaffective disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(7):1065-70.
Taedt J, Stoppe G, Hajak G. et al. Rebound insomnia after abrupt clozapine withdrawal. Eur Arch Psychiatry Clin Nuerosci 1996; 246:79–82.
Galova A, Berney P, Desmeules J. et al. A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder. BMC Psychiatry 2019;73.
Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl) 2006;185(3):265-73.
Reddig S, Minnema AM, Tandon R. Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry 1993;5(1):25-27.
Ganelin L, Lichtenberg PS, Marcus EL, Munter RG. Suspected neuroleptic malignant syndrome in a patient receiving clozapine. Ann Pharmacother 1996;30(3):248-50.
Miller DD, Sharafuddin MJ, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991;52(3):99-101.
Farah A. Clozapine and Neuroleptic Malignant Syndrome: Case Report and Risk Analysis of Monotherapy vs. Combination Therapy. J Clin Pharm 2017;3(1):1013.
Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Current Neuropharmacology 2012;10(1):88-95.
Kim DD, Barr AM, White RF, Honer WG, Procyshyn RM. Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatment. J Psychiatry Neurosci 2019;44(1):71-72.
Downloads
Published
How to Cite
Issue
Section
